Initial Treatment of Ketosis-Prone Diabetes

Immediate Management Based on Presentation Severity

The American Diabetes Association recommends starting insulin immediately using either intravenous or subcutaneous routes depending on severity in patients with ketoacidosis, with a goal of rapidly correcting hyperglycemia and metabolic derangement 3, 1, 4
For severe DKA requiring hospitalization, the American Diabetes Association suggests using continuous intravenous regular insulin infusion until acidosis resolves, with resolution criteria including glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, and venous pH ≥7.3 5
Once acidosis resolves, the American Diabetes Association recommends initiating metformin (starting at 500 mg daily, titrating up to 2000 mg daily in divided doses) while continuing subcutaneous insulin, with a strength of evidence based on high-quality clinical trials 3, 1, 4

The American Diabetes Association notes that a substantial percentage of youth with type 2 diabetes present with clinically significant ketoacidosis, making diabetes type uncertain initially, and recommends treating all patients presenting with ketosis/ketoacidosis with insulin initially, regardless of suspected diabetes type 3, 4
The American Diabetes Association suggests sending pancreatic autoantibodies (GAD, IA-2, ZnT8) to differentiate type 1 from ketosis-prone type 2 diabetes, with a recommendation to continue with type 2 diabetes management (insulin + metformin with eventual insulin taper) if autoantibodies are negative, and to continue multiple daily injection insulin therapy as for type 1 diabetes and discontinue metformin if autoantibodies are positive 7, 8

The American Diabetes Association recommends tapering insulin over 2-6 weeks for patients meeting glucose targets on home blood glucose monitoring, with a decrease in insulin dose by 10-30% every few days, and continuing metformin throughout the taper 3, 1, 2

The American Diabetes Association suggests checking blood glucose every 2-4 hours during acute insulin therapy, and measuring A1C every 3 months after stabilization, with a goal of assessing serum electrolytes, particularly potassium, every 2-4 hours during DKA treatment 5, 3, 1

The American Diabetes Association recommends aiming for A1C <7% (53 mmol/mol) for most patients on oral agents alone, with a strength of evidence based on high-quality clinical trials, and considering more stringent targets of <6.5% (48 mmol/mol) for patients achieving significant weight improvement on metformin and lifestyle modification 1, 2